Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. ContraVir Pharmaceuticals
CTRV

Buy ContraVir Pharmaceuticals (CTRV) Stock

CTRV
See CTRV stock price and Buy/Sell ContraVir Pharmaceuticals with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
CTRV

ContraVir Pharmaceuticals (CTRV)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About ContraVir Pharmaceuticals (CTRV)

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Market Cap
$53.61M
1 Year High
$1.85
Volume
—
1 Year Low
$0.49
Price to Earnings Ratio
—
Open
—
Dividend Rate
—
High
—
Dividend Yield
—
Low
—

Community

People who own or watch CTRV stock

ContraVir Pharmaceuticals Stock News

Benzinga •
ContraVir Rebounds From Record Low On Positive FDA Feedback

ContraVir Pharmaceuticals stock rating

What analysts recommend for CTRV stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell

ContraVir Pharmaceuticals price target

What analysts think CTRV will be worth
Low $0
High $1.85
Current $0
Target $0

Buy ContraVir Pharmaceuticals (CTRV) Stock

CTRV
See CTRV stock price and Buy/Sell ContraVir Pharmaceuticals with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch CTRV stock
  • mv67 avatar
  • Kmainor avatar
  • Adawnisrising avatar
  • AIAPilot avatar
  • RichDad avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

View Full Disclosures